Madrigal PharmaceuticalsMDGL
Recorded

Madrigal Pharmaceuticals 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 2 minParticipants18

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, and thank you for standing by. Welcome to Madrigal Pharmaceuticals' third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. As a reminder, today's conference call is being recorded. I would now like to introduce Ms. Tina Ventura, Chief Investor Relations Officer.

Tina VenturaChief Investor Relations Officer

Please go ahead. Thanks. Good morning, everyone, and thank you for joining us to discuss Madrigal's third quarter 2026 results.

Tina VenturaChief Investor Relations Officer

We issued a press release this morning and posted a slide deck to accompany this webcast on the Investor Relations section of our website. On the call with me today are Bill Sibold, Chief Executive Officer, Dave Soergel, Chief Medical Officer, and Mardi Dier, Chief Financial Officer. They will provide prepared remarks, followed by Q&A. Please note that on slide 2, we will be making certain forward-looking statements today. We refer you to our SEC filings for a discussion of the risks that may cause actual results to differ from the forward-looking statements. With that, I will now turn the call over to Bill on slide 3.

Bill SiboldCEO

Thanks, Tina, and thank you all for joining. The business is performing exceptionally well. REZDIFFRA is growing rapidly, and the MASH market is accelerating. REZDIFFRA's best-in-disease profile and our team's strong execution have established REZDIFFRA as the foundational therapy in MASH. I'll summarize a few highlights. First, we delivered a $431 million quarter, crossed the $1 billion milestone in year-to-date net sales, and are now annualizing at more than $1.7 billion based on this quarter's results. We're continuing to steadily add patients and believe we're well on our way to mega-blockbuster status. Second, the U.S. F2/F3 MASH market is accelerating, on track to grow more than 30% this year. When you combine rapid market growth with REZDIFFRA's patent protection expected into 2045, it's hard to find a more attractive growth opportunity in biotech.

Bill SiboldCEO

Third, we're advancing our F4C program with the same objective that has guided us in F2/F3, to be first and best. Our ongoing MAESTRO-NAFLD OUTCOMES trial positions us to deliver the first approved therapy for F4C. Our new MAESTRO-CSPH phase III trial is designed to be a practice-shaping trial that we expect to extend our competitive advantage and strengthen our long-term leadership. Let's move to our Q3 results, where I'll cover REZDIFFRA and the expanding MASH market. Dave will discuss our pipeline progress, and Mardi will close with our financials. Turning to slide 5, third quarter 2026 net sales were $431 million, up 50% year-over-year. This performance reflects growing demand for REZDIFFRA and outstanding execution by our team. We built a broad and durable prescriber base early, and now we are driving depth.

Bill SiboldCEO

The positive experience our target specialists are having with REZDIFFRA in the real world is translating into action. They are prescribing it more often. That growing depth, combined with excellent access, REZDIFFRA's differentiated profile, and strong patient adherence, is why we continue to steadily add patients. As shown on slide 6, we ended the third quarter with more than 55,850 active REZDIFFRA patients, compared to more than 29,500 a year ago. That's nearly twice as many patients on therapy. As a reminder, this is the number of patients actively on therapy at quarter end, net of discontinuations. Slide 7 shows why we are so confident in the opportunity ahead. Our latest research shows that the market is accelerating. As we said, at the end of 2025, the diagnosed U.S. F2/F3 MASH population had grown nearly 50% in two years to 460,000 patients.

Bill SiboldCEO

As of June 30th of this year, we estimate the market expanded to more than 530,000 patients and is on track to grow more than 30% by the end of 2026. The growth in this market is primarily being driven by an increase in awareness and diagnosis. Slide 8 makes clear just how much runway remains. The MASH diagnosis rate is still only around 10%, and REZDIFFRA has penetrated approximately 10% of the market. At 10% of 10%, we are only about 1% into the total opportunity. With more than $1 billion in year-to-date net sales, we are at the very beginning of what we believe will become one of the largest specialty markets in the industry. As noted on slide 10, building a successful medicine takes much more than a positive top-line readout. That's only the beginning of the story. Launch success depends on several important drivers.

Bill SiboldCEO

Labels matter. Boxed warnings and burdensome monitoring requirements create barriers. You need efficacy, safety, and tolerability to translate into a positive real-world experience. You need a medicine that is easy to prescribe, easy to take, and easy to stay on. Then there's execution, the right infrastructure, the field team, medical affairs, reimbursement, market access, fulfillment, and patient support all working together to get patients on therapy and keep them on therapy. Building that system takes experience, resources, and time. Ten quarters into launch, those questions have been answered for REZDIFFRA, as shown on slide 11. We have what we believe is the best-in-disease profile. REZDIFFRA is highly effective across each patient subtype. It's well tolerated and simple to use, and with nearly 56,000 patients on therapy, its safety profile is exceptionally well defined, which actually may be the most important thing.

Bill SiboldCEO

That's the real-world profile you want for a chronic disease. We also built the industry-leading infrastructure, and we are continuously improving it. We've done the hard work to wire the system and have set an extremely high bar. This doesn't just happen overnight, and it is difficult to replicate. We already have thousands of prescribers and more than two years of real-world experience. Any new entrant will have to build what we are already optimizing and answer the question, what problem are they trying to solve? We have delivered one of the best specialty launches of the last decade and established clear leadership in F2, F3 by being first and best. We will leverage this formidable advantage in F4C as well. Let's turn to slide 12. The F4C market is increasingly attractive. It's a rapidly growing multi-billion dollar market opportunity.

Bill SiboldCEO

We now estimate 360,000 addressable F4C patients in the U.S., up more than 45% from the 245,000 we previously shared. That is larger than the F2, F3 patient population when we launched REZDIFFRA. Expanding into F4C could double REZDIFFRA's opportunity and bring patients their first approved therapy. We have also seen recently that competitors have modified their programs, increased their study sizes, and delayed their timelines, with the earliest potential entrant now not expected until 2030. Our lead in F4C has widened. MAESTRO-NASH-OUTCOMES puts us in a unique position to be first to market. Events continue to accrue in this study, and we are now anticipating a readout in late 2027. We are confident in REZDIFFRA's potential in F4C and are exceptionally well positioned to lead. The addition of our new phase III trial, MAESTRO-CSPH, raises the bar for the field.

Bill SiboldCEO

It builds on MAESTRO-NASH-OUTCOMES while unlocking new opportunities to shape clinical practice as the treatment landscape continues to evolve. This trial will benefit from what we have learned about F4C over the last five years and is another tangible demonstration of our leadership in MASH. Our objective remains clear: be first and best in F4C. Dave will walk you through our plans. Over to you, Dave. Thanks, Bill.

David SoergelChief Medical Officer

Patients with F4C MASH face serious risks, including liver decompensation, liver cancer, and premature death. The unmet need is urgent. Our two-year data from the 122-patient open-label F4C cohort in MAESTRO-NAFLD-1 shows that patients treated with REZDIFFRA for two years have improved MASH-related biomarkers and imaging parameters. Among the patients with clinically significant portal hypertension, or CSPH, confirmed at baseline, 65% moved to a lower risk category, suggesting a lower risk of liver decompensation. These data reinforce our confidence in REZDIFFRA's potential to benefit these patients. MAESTRO-NASH-OUTCOMES gives us the opportunity to deliver the first approved treatment for F4C. This is our 845-patient, placebo-controlled, event-driven phase III trial. The primary endpoint is improvement in liver-related clinical outcomes, consistent with FDA guidance. A positive result would support both an F4C indication and full approval across F2 through F4C MASH.

David SoergelChief Medical Officer

We continue to accrue events, and as Bill referenced, we now anticipate a readout in late 2027. In parallel, we plan to initiate MAESTRO-CSPH in the first half of 2027. This second phase III outcomes trial will draw on our open-label F4C data, our experience conducting MAESTRO-NASH-OUTCOMES, and the latest advances in the field to generate highly relevant data to support REZDIFFRA's benefit in F4C. There are four features that distinguish this new trial and our F4C program, as noted on slide 14. First is the patient population. We plan to enroll more than 2,000 patients and enrich the trial for CSPH. Development of CSPH is a critical inflection point in the pathophysiology of compensated cirrhosis, so we are focusing this new trial where the unmet need is greatest and where preventing or delaying a clinical event is especially meaningful. Second is the breadth of evidence we intend to generate.

David SoergelChief Medical Officer

We expect to have the most comprehensive data set in F4c. The size of this new trial, combined also with MAESTRO-NASH OUTCOMES, should allow us to conduct meaningful analyses across clinically important subgroups. Third, MAESTRO-CSPH enhances our opportunity to build REZDIFFRA-specific biomarker evidence. We plan to collect a rich set of biomarkers and noninvasive data in MAESTRO-CSPH, as we've done in MAESTRO-NASH OUTCOMES. Using the data from MAESTRO-NASH OUTCOMES, we can identify measures that are most closely associated with treatment benefit and potentially validate those findings in MAESTRO-CSPH. Fourth is scale. Across MAESTRO-NASH OUTCOMES and MAESTRO-CSPH, we expect our F4c outcomes-based clinical program to include approximately 3,000 patients, which will give us the greatest insight into this population and further strengthen our competitive advantage. Overall, we believe MAESTRO-CSPH will be the defining F4c study in this space.

David SoergelChief Medical Officer

We plan to finalize the study protocol following our discussions with FDA and initiate the study in the first half of next year, with results expected in the early 2030s. Having two complementary outcomes trials gives us a unique advantage and the opportunity to demonstrate consistent clinical benefit across studies, replicate key biomarker findings, advance the science in F4c, and give prescribers a more complete understanding of REZDIFFRA. Now let's turn to what we're doing today to further expand the evidence base supporting REZDIFFRA in F2, F3. In a heterogeneous disease like MASH, predictable efficacy across patient subgroups is critical for patients and providers. The forest plot on slide 15 from our phase III MAESTRO-NASH trial demonstrates REZDIFFRA's consistent efficacy across each patient subgroup, including patients with F2 or F3 fibrosis, with or without type 2 diabetes, across BMI categories, and across common genetic variants.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day